Business, energy, technology, markets and global industry news from Business News Today

BOT+BAL

PharmaDeviceNews BOT+BAL
Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.
Pharma & Biotech

Agenus BOT+BAL shows long-term survival in refractory MSS colorectal cancer

Agenus reports durable BOT+BAL survival in refractory MSS colorectal cancer, but a post-hoc Phase 1b analysis still needs randomised confirmation.

Read More
Representative image: Oncology specialists review colorectal cancer scans and survival data as Agenus prepares to present three-year BOT+BAL findings in MSS metastatic colorectal cancer at ESMO GI 2026.
Pharma & Biotech

Agenus prepares ESMO GI 2026 survival update as BOT+BAL enters its Phase 3 test

Read how Agenus’ three-year BOT+BAL survival update could reshape expectations in refractory MSS metastatic colorectal cancer.

Read More